Twin Tree Management, LP Bristol Myers Squibb CO Put Options Transaction History

Twin Tree Management, LP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 May 11, 2022	BUY	$61.48 - $73.72 $33.7 Million - $40.4 Million	548,500 Added 2715.35%	568,700 $41.5 Million
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $1.72 Million - $1.95 Million	-29,800 Reduced 59.6%	20,200 $1.25 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $18.2 Million - $20.2 Million	-317,700 Reduced 86.4%	50,000 $3.02 Million
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $25 Million - $32.6 Million	-507,400 Reduced 57.98%	367,700 $23.6 Million
Q3 2019 Nov 12, 2019	BUY	$42.77 - $50.71 $354,991 - $420,893	8,300 Added 0.96%	875,100 $44.4 Million
Q2 2019 Aug 12, 2019	BUY	$44.62 - $49.34 $32.2 Million - $35.6 Million	720,600 Added 492.89%	866,800 $39.3 Million
Q1 2019 May 10, 2019	SELL	$45.12 - $53.8 $17 Million - $20.2 Million	-375,800 Reduced 71.99%	146,200 $6.98 Million
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $24.7 Million - $32 Million	506,400 Added 3246.15%	522,000 $27.1 Million
Q3 2018 Nov 09, 2018	SELL	$55.19 - $62.25 $3.48 Million - $3.92 Million	-63,000 Reduced 80.15%	15,600 $968,000
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $4.34 Million - $5.01 Million	78,600	78,600 $5.01 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

Stay updated on Twin Tree Management, LP with notifications on news.